PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
15235103-9	2004	Together, these findings are consistent with the notion that although inhibition of NF-kappaB activation by flavopiridol contributes to antileukemic interactions with HDACIs, other NF-kappaB-independent flavopiridol actions (e.g., down-regulation of Mcl-1, XIAP, and p21CIP1/WAF1) play particularly critical roles in this phenomenon.	alvocidib	108-120	nuclear factor kappa B subunit 1	Homo sapiens	84-93	
27771926-5	2016	Recent studies indicate that flavopiridol elicits anti-inflammatory activity via CDK9 and NFkappaB-dependent signaling.	alvocidib	29-41	nuclear factor kappa B subunit 1	Homo sapiens	90-98	
15235103-1	2004	Interactions between the cyclin-dependent kinase inhibitor flavopiridol and the histone deacetylase inhibitors (HDACIs) sodium butyrate (NaB) and suberoylanilide hydroxamic acid (SAHA) have been examined in human leukemia cells in relation to effects on nuclear factor kappaB (NF-kappaB) activation.	alvocidib	59-71	nuclear factor kappa B subunit 1	Homo sapiens	277-286	
15235103-2	2004	Exposure (24 h) of U937 human leukemia cells to NaB (1 mM) or SAHA (1.5 microM) resulted in a marked increase in NF-kappaB DNA binding, effects that were essentially abrogated by coadministration of flavopiridol (100 nM).	alvocidib	199-211	nuclear factor kappa B subunit 1	Homo sapiens	113-122	
15235103-5	2004	However, disruption of the NF-kappaB pathway also increased mitochondrial injury and caspase activation in response to flavopiridol and to an even greater extent to the combination of flavopiridol and HDACIs.	alvocidib	119-131	nuclear factor kappa B subunit 1	Homo sapiens	27-36	
15235103-5	2004	However, disruption of the NF-kappaB pathway also increased mitochondrial injury and caspase activation in response to flavopiridol and to an even greater extent to the combination of flavopiridol and HDACIs.	alvocidib	184-196	nuclear factor kappa B subunit 1	Homo sapiens	27-36	
12566305-9	2003	In contrast, flavopiridol was found to inhibit the NF-kappa B-dependent gene transcription, which might give an explanation for the synergistic effect of flavopiridol with TNF-alpha.	alvocidib	13-25	nuclear factor kappa B subunit 1	Homo sapiens	51-61	
12566305-9	2003	In contrast, flavopiridol was found to inhibit the NF-kappa B-dependent gene transcription, which might give an explanation for the synergistic effect of flavopiridol with TNF-alpha.	alvocidib	154-166	nuclear factor kappa B subunit 1	Homo sapiens	51-61	
12419552-5	2002	Similarly, insulin-like drugs target the nuclear receptor peroxisome-proliferator-activator-receptor (PPAR)-gamma (class-II), several anti-inflammatory drugs inhibit activation of nuclear factor kappa B (NFkappaB) (class-IV), while others (e.g. flavopiridol, rapamycin, and paclitaxel) target regulation of cell-cycle proteins.	alvocidib	245-257	nuclear factor kappa B subunit 1	Homo sapiens	180-202	
12419552-5	2002	Similarly, insulin-like drugs target the nuclear receptor peroxisome-proliferator-activator-receptor (PPAR)-gamma (class-II), several anti-inflammatory drugs inhibit activation of nuclear factor kappa B (NFkappaB) (class-IV), while others (e.g. flavopiridol, rapamycin, and paclitaxel) target regulation of cell-cycle proteins.	alvocidib	245-257	nuclear factor kappa B subunit 1	Homo sapiens	204-212